1207529-80-3

Upstream product

• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 62456-15-9 methyl trans-4-amino-cyclohexanecarboxylate 
• 239074-29-4 trans (4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 1319743-51-5 trans-1-(4-amino-cyclohexylmethyl)-3,3-dimethyl-1,3-dihydro-indol-2-one 
• 1319743-42-4 trans-N-[4-(3,3-dimethyl-2-oxo-2,3-dihydro-indol-1-ylmethyl)-cyclohexyl]-4-fluoro-3-trifluoromethyl-benzamide 

Relevant academic research and scientific papers

1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE

The purpose of the present invention is to provide a compound having PIM inhibitory activity. Examples of the present invention include 1,3,4-oxadiazolone compounds represented by the following formula [1], and pharmaceutically acceptable salts, and solvates thereof. The compounds of the present invention have PIM inhibitory activity. In addition, since the compounds of the present invention have PIM inhibitory activity, the compounds of the present invention are useful as therapeutic agents for systemic lupus erythematosus, lupus nephritis, etc.

CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS

There are described cydohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists